Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02831179
Title Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

VIPoma

thyroid gland medullary carcinoma

islet cell tumor

adrenal medulla cancer

insulinoma

adrenal carcinoma

somatostatinoma

Merkel cell carcinoma

small intestine carcinoid neuroendocrine tumor

L-cell glucagon-like peptide producing tumor

neuroendocrine tumor

gastrinoma

Therapies

Capecitabine + Temozolomide + Veliparib

Age Groups: adult | senior
Covered Countries


No variant requirements are available.